Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
4 min read
BioLineRx reveals FDA approval for APHEXDA™ (motixafortide) to stimulate stem cell collection for autologous transplant in Multiple Myeloma patients
19 September 2023
BioLineRx Discloses FDA Authorization for APHEXDA™ (motixafortide), to Activate Hematopoietic Stem Cells for Gathering and Subsequent Autologous Transplantation in Multiple Myeloma Patients.
Drug Insights
4 min read
Ixabepilone: Detailed Review of its Transformative R&D Success
19 September 2023
This article summarized the latest R&D progress of Ixabepilone, the Mechanism of Action for Ixabepilone, and the drug target R&D trends for Ixabepilone.
Valuable Targets
6 min read
Another Potential Stock after PD1 - LAG3 Inhibitors
19 September 2023
The Lymphocyte-activation gene-3 (LAG-3) is located on human chromosome 12 (20p13.3), includes 8 exons, and its corresponding cDNA encodes a membrane protein containing 498 amino acids.
Drug Insights
4 min read
Fosaprepitant Dimeglumine Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
19 September 2023
This article summarized the latest R&D progress of Fosaprepitant Dimeglumine, the Mechanism of Action for Fosaprepitant Dimeglumine, and the drug target R&D trends for Fosaprepitant Dimeglumine.
Latest Hotspot
4 min read
Takeda Reveals Promising Initial Findings from Phase 2b Trial Examining TAK-279, aimed at treatment of Active Psoriatic Arthritis
19 September 2023
Takeda has shared positive initial results from its Phase 2b trial, on TAK-279, a selective, orally administered TYK2 inhibitor, which is assessed for its efficacy in treating active psoriatic arthritis.
Drug Insights
4 min read
Unleashing the Power of Ephedrine Hydrochloride: A Comprehensive Review on R&D Breakthroughs
19 September 2023
This article summarized the latest R&D progress of Ephedrine Hydrochloride, the Mechanism of Action for Ephedrine Hydrochloride, and the drug target R&D trends for Ephedrine Hydrochloride.
Advanced Tech.
7 min read
A type of emerging tumor treatment drug: Aptamers
19 September 2023
Aptamers are short nucleotide sequences, typically DNA or RNA of 20 to 100 nucleotides.
Drug Insights
4 min read
A Comprehensive Review of Eliglustat's R&D Innovations and Drug Target Mechanism
18 September 2023
This article summarized the latest R&D progress of Eliglustat, the Mechanism of Action for Eliglustat, and the drug target R&D trends for Eliglustat.
Latest Hotspot
3 min read
Lisata Therapeutics reports the initial treatment of a patient in the BOLSTER Trial involving LSTA1, for patients with solid tumors
18 September 2023
LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively.
Drug Insights
4 min read
Pharmaceutical Insights: Doripenem's R&D Progress and its Mechanism of Action on Drug Target
18 September 2023
This article summarized the latest R&D progress of Doripenem, the Mechanism of Action for Doripenem, and the drug target R&D trends for Doripenem.
Valuable Targets
5 min read
Regulating tumor immune suppression, the therapeutic effect of the new generation CSF-1R inhibitors is encouraging
18 September 2023
CSF-1 exerts its effects by binding to a receptor called colony stimulating factor 1 receptor (CSF-1R), also known as c-FMS, leading to a signaling pathway cascade.
Drug Insights
4 min read
Exploring Dihydroergotamine Mesylate's Revolutionary R&D Successes
18 September 2023
This article summarized the latest R&D progress of Dihydroergotamine Mesylate, the Mechanism of Action for Dihydroergotamine Mesylate, and the drug target R&D trends for Dihydroergotamine Mesylate.